

- TBDWG 2018 7.7b Testing and Diagnostic Bands: How They Are Used Today and What That Is Doing to Patients: Engage Diverse Stakeholders—Update the CSTE Surveillance Case Definition with 21st-Century Evidence

- TBDWG 2020 3.1 Implement multi-agency, ecologically-based One Health efforts on tick-borne diseases promoting research and enhanced vector surveillance to identify and *validate integrated tick management* in keystone wildlife hosts, particularly white-tailed deer, and the sustainable management of their populations.

- TBDWG 2020 8.2 Recommend that CDC work with Council of State and Territorial Epidemiologists (CSTE) to *streamline* the surveillance process and to reduce the burden on both clinicians and public health departments by permitting direct laboratory reporting of positive cases.

*Strategic Priority 4: Respond to Public Health emergencies resulting from VBD threats.*

*Strategic Priority 5: Clarify, facilitate, and improve processes to bring regulated diagnostic tests, treatment strategies, vaccines, and vector control products to market.*

Although critical to public health and wellness, the following recommendations related to healthcare utilization, access to care, reimbursement or payment for clinical services, and legal protections are outside the scope of this prevention and control strategy:

- TBDWG 2018 3.3 Support economic studies and activities to estimate the total cost of illness associated with tick-borne diseases in the United States, beginning first with Lyme disease and including both financial and societal impacts.

- TBDWG 2018 7.3 Ensure the rights of those dealing with Lyme disease and tick-borne diseases and conditions by reducing the burden of the processes under which patients are currently diagnosed and treated and by which they access care. Basic protections must include, but not necessarily be limited to, those that protect patients from employment discrimination.

- TBDWG 2018 7.4 Ensure the rights of those dealing with Lyme disease and tick-borne diseases and conditions by reducing the burden of the processes under which patients are currently diagnosed and treated and by which they access care. Basic protections must include, but not necessarily be limited to, those that protect students of all ages from discrimination.

- TBDWG 2018 7.5 Ensure the rights of those dealing with Lyme disease and tick-borne diseases and conditions by

reducing the burden of the processes under which patients are currently diagnosed and treated and by which they access care. Basic protections must include, but not necessarily be limited to, those that protect patients from health care and disability insurance coverage and reimbursement policies that are unduly burdensome.

- TBDWG 2018 7.6 Ensure the rights of those dealing with Lyme disease and tick-borne diseases and conditions by reducing the burden of the processes under which patients are currently diagnosed and treated and by which they access care. Basic protections must include, but not necessarily be limited to, those that protect the rights of licensed and qualified clinicians to use individual clinical judgment, as well as recognized guidelines, to diagnose and treat patients in accordance with the needs and goals of each individual patient.

- TBDWG 2020 9.6 CMS: Recommend that CMS provides all information and data on Lyme disease and other tick-borne diseases and all applicable agency activities pertaining to these conditions which may include but should not be limited to:

- Reimbursement costs for the diagnosis and treatment of beneficiaries with Lyme disease and other tick-borne diseases;

- Demonstration and pilot projects with Lyme disease and other tick-borne diseases as their focus; and

- Quality measure development and implementation related to Lyme disease and other tick-borne diseases.

[FR Doc. 2022–25241 Filed 11–18–22; 8:45 am]

**BILLING CODE 4150–28–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Assistant Secretary for Health; Opportunity To Co-Sponsor OASH-Supported Grantee Workshops

**AGENCY:** Office of the Assistant Secretary for Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The Grants and Acquisitions Management Division (GAM) in the Office of the Assistant Secretary for Health (OASH), in conjunction with the grant making program offices it supports, announces the opportunity for non-federal public and private sector entities to co-sponsor OASH-supported grants workshops (OASH Grants Workshops). Potential co-sponsors must have a demonstrated interest and experience in building capacity among potential grant applicants and grant

recipients. Potential co-sponsors must be willing to participate substantively in the co-sponsored activity. Expressions of interest for co-sponsorships of OASH Grants Workshops are received throughout the year at the email address below. OASH intends to co-sponsor a limited number of workshops with other entities each year. Expressions of interest are being received for OASH Grants Workshops that will take place in the next fiscal year (October 2022 through September 2023) or beyond. Expressions of interest for co-sponsorships should be sent by email to [OASH\\_Grants@HHS.GOV](mailto:OASH_Grants@HHS.GOV) with “Co-sponsorship for OASH-supported Grants Workshops” in the subject field or by mail to Duane Barlow, Grants Branch Chief, OASH, Grants and Acquisitions Management Division, at 1101 Wootton Parkway, Plaza Level, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:**

Duane Barlow, Grants Branch Chief, OASH, Grants and Acquisitions Management Division, 1101 Wootton Parkway, Plaza Level, Rockville, MD 20852; or via phone (240) 453–8822.

**SUPPLEMENTARY INFORMATION:** The OASH Grants and Acquisitions Management (GAM) Division oversees, administers, and supports grant-making activities of public health offices on behalf of the Secretary of the U.S. Department of Health and Human Services (HHS). The grant-making program offices that GAM supports include: the Office of Infectious Disease and HIV/AIDS Policy (OIDP), Office of Minority Health (OMH), Office of Population Affairs (OPA), Office of Research Integrity (ORI), and Office on Women’s Health (OWH). Another OASH component, the Office of Regional Health Operations (ORHO), which includes ten Regional Offices covering all states and territories of the United States and three independent states in the Pacific, through its coordinating function will also be involved in the OASH Grants Workshops.

Consistent with each office’s mission and applicable statutory authority, the OASH Grants Workshops aim to build capacity among potential grant applicants and grant recipients in related areas such as applying for and managing grants and cooperative agreements (collectively grants) awarded under the programs listed by Assistance Listing number below:

- 93.007 Public Awareness Campaigns on Embryo Adoption
- 93.085 Research on Research Integrity
- 93.088 Advancing System Improvements for Key Issues in Women’s Health

- 93.137 Community Programs to Improve Minority Health Grant Program
- 93.217 Family Planning Services
- 93.260 Family Planning Personnel Training
- 93.297 Teenage Pregnancy Prevention Program
- 98.343 Public Health Service Evaluation Funds
- 93.344 Research, Monitoring and Outcomes Definitions for Vaccine Safety
- 93.974 Family Planning Service Delivery Improvement Research Grants

Full Assistance Listing descriptions are published and updated annually on <https://sam.gov>. Co-sponsors will work with OASH/GAM staff to jointly develop an event. Both OASH and the co-sponsor must contribute substantively to the development of the event.

OASH Grants Workshops may be convened over one to three days; conducted virtually, in-person, or in a hybrid format (virtual and in-person). Depending on the workshop format and scope, a workshop may typically accommodate between 100 and 500 attendees.

Co-sponsors can charge registration fees to recover costs associated with the events; however, co-sponsors may not set registration fees at an amount higher than necessary to recover related event expenses. Further, co-sponsors are solely responsible for collecting and handling any registration fees collected.

**Eligibility for Co-Sponsorship:** The co-sponsoring entity must have a demonstrated interest and experience in building capacity among potential grant applicants and grant recipients, particularly with respect to programs supported by GAM. The co-sponsoring entity must participate substantively in the co-sponsored activity, not just provide funding, logistical services, or other material support.

Each potential co-sponsorship's expression of interest shall describe:

- (1) The entity's interest in building capacity among potential grant applicants and grant recipients,
- (2) The entity's prior experience and current readiness to undertake the responsibilities described above,
- (3) The type of event(s) that the entity is interested in co-sponsoring with GAM,
- (4) Facilities and/or virtual platforms available for the event(s), and
- (5) Any current constraints with respect to dates or facilities.

The type of event may be a special topic of mutual interest with one or

more of the aforementioned GAM supported program offices and may be developed jointly.

The expression of interest should be a bulleted outline, no more than two pages in length, single-spaced, and 11-point font. An entity may submit an expression of interest individually or jointly with other entities describing their relative contributions.

**Evaluation Criteria:** After engaging in exploratory discussions with potential co-sponsors that respond to this notice, the following considerations will be used by HHS officials, as appropriate and relevant, to select the co-sponsor(s):

- Qualifications and capability to fulfill co-sponsorship responsibilities
- Suitability of the location of the proposed OASH Grants Workshops in terms of the overall geographical distribution of OASH Grants Workshops
- Potential for reaching, generating, and engaging an adequate number of attendees who may be potential grant applicants and grant recipients
- Availability and description of facilities and resources needed to support the OASH Grants Workshop
- Availability of administrative support for the logistics of hosting such OASH Grants Workshops

These duties will be outlined in a co-sponsorship agreement with GAM and the sponsoring program office(s) that will set forth the details of the co-sponsored activity, including the requirements that any fees collected by the co-sponsor shall be limited to the amount necessary to cover the co-sponsor's related event expenses. This co-sponsorship agreement does not represent an endorsement by HHS, OASH, GAM or its supported program office(s) of an individual co-sponsor's policies, positions, or activities.

Additionally, this agreement will not affect any determination concerning activities by the co-sponsors that are regulated by GAM's grant-supporting offices.

Dated: November 14, 2022.

**Scott J. Moore,**

*Director, Grants and Acquisitions Management Division, Office of the Assistant Secretary for Health.*

[FR Doc. 2022-25259 Filed 11-18-22; 8:45 am]

**BILLING CODE 4150-28-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Library of Medicine; Cancellation of Meeting

Notice is hereby given of the cancellation of the National Library of Medicine Special Emphasis Panel, March 16, 2023, 11 a.m. to 3 p.m., Virtual Meeting, which was published in the **Federal Register** on October 6, 2022, 87 FR 193 Page Number 60696.

This notice is being amended to announce that the meeting is cancelled and will not be rescheduled.

Dated: November 16, 2022.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022-25317 Filed 11-18-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; RFA-DK-22-004 NIDDK Partnerships with Professional Societies to Enhance Scientific Workforce Diversity and Promote Scientific Leadership.

**Date:** December 16, 2022.

**Time:** 2:00 p.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2 Democracy, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

**Contact Person:** John F. Connaughton, Ph.D., Chief, Scientific Review Branch, Review Branch, DEA, Niddk National Institutes of Health, Room 7007, 6707